Shots: Dragonfly Therapeutics will receive an upfront $695M with milestone and royalties on sales and Merck to get option to license exclusive worldwide IPR rights of products developed using Dragonfly’s […]readmore
Tags : Merck
Shots: • CHMP approval is based on two P-III trials i.e. DRIVE-AHEAD and DRIVE-FORWARD assessing (Delstrigo vs efavirenz (EFV)/emtricitabine (FTC)/TDF) and (Pifeltro vs darunavir +ritonavir +FTC/TDF/abacavir (ABC)/3TC)) for 48 wks., […]readmore
Shots: The approval is based on KEYNOTE-189 P-III study, assessing (KEYTRUDA + pemetrexed ALIMTA and Pt CT vs CT alone) administering KEYTRUDA 200 mg, cisplatin/carboplatin, and pemetrexed q3w IV for […]readmore
Shots: The approval is based on P-III DRIVE-FORWARD study assessing Pifeltro (qd) vs darunavir + ritonavir (DRV+r) (800mg, 100 mg, qd) each in combination with emtricitabine (FTC)/TDF or abacavir (ABC)/3TC […]readmore
Shots: Post FDA approval, Lenvima receives EU approval for oral RTKi for the treatment of advanced or unresectable HCC The approval is based on REFLECT study results: (Lenvima vs Sorafenib): […]readmore
Shots: Approval is based on KEYNOTE-189, Ph III study where Keytruda combined with ALIMTA and Pt. CT showed improved results vs CT KEYNOTE-189 (Keytruda +pemetrexed and Pt. CT vs CT […]readmore
Shots: Approval is based on positive results of Ph III REFLECT study showing improved OS, PFS and ORR REFLECT results (Lenvima vs Sorafenib): mOS (13.6 vs 12.3 mos), mPFS (7.3 […]readmore
Shots: Under the expansion collaboration, new arm of assessment is added assessing BL-8040, Keytruda and chemo in 2L patient in COMBAT/KEYNOTE-202 study Results of Ph2a COMBAT study is expected in […]readmore